Chemical Business NewsBase - Press Release:; ChemoCentryx Inc reports publication of positive Phase II data with CCX354.
In: Chemical Business NewsBase (UK), 2012-06-08, S. 3
Zeitungsartikel
Zugriff:
ChemoCentryx Inc announced publication of positive data from the 's Phase II CARAT-2 study for CCX354, a potent and selective, orally-administered inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA). The findings showed that CCX354 was generally well tolerated by patients with RA...
Titel: |
Chemical Business NewsBase - Press Release:; ChemoCentryx Inc reports publication of positive Phase II data with CCX354.
|
---|---|
Zeitschrift: | Chemical Business NewsBase (UK), 2012-06-08, S. 3 |
Veröffentlichung: | 2012 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|